Effect of Carfilzomib in the treatment of advanced myeloma

Carfilzomib (Carfilzomib), as a targeted therapy, has shown significant results in the treatment of advanced myeloma (Multiple Myeloma). Multiple myeloma is a malignant tumor that usually occurs in plasma cells in the bone marrow and is characterized by abnormal proliferation and accumulation in the skeletal system, causing bone damage and the production of abnormal proteins. Patients with advanced myeloma generally refer to those whose disease has progressed after multiple rounds of treatment, including refractory and relapsed disease. The following is the effect of carfilzomib in the treatment of advanced myeloma:

1. Controlling disease progression: The efficacy of carfilzomib is excellent in controlling the progression of advanced myeloma. As a proteasome inhibitor, it promotes the accumulation of abnormal proteins in cancer cells by inhibiting the function of the proteasome, ultimately leading to the death of these cancer cells. For those patients who have received multiple rounds of treatment, carfilzomib offers a new treatment option that can effectively control disease progression.

2. Prolong survival time: Clinical trial data of carfilzomib treatment show that it can significantly extend the survival time of patients with advanced myeloma. Particularly in patients with relapsed and refractory multiple myeloma, the addition of carfilzomib provided longer progression-free survival (PFS) and overall survival (OS) compared with traditional treatments. This means patients have more time to manage their disease, enjoy life, and find other treatment options.

3. Sustainability of efficacy: A key advantage is that responses to carfilzomib treatment generally last for a longer period of time. This means patients are more likely to maintain stable disease rather than rapidly progressing. This is an important advantage for patients with advanced myeloma because it provides more time to organize treatment and life.

4. Improved quality of life: Treatment with carfilzomib is also associated with improved quality of life. By controlling the progression of the disease and reducing pain and other symptoms, carfilzomib can help patients better cope with the challenges of disease and treatment. This is very important for patients with advanced myeloma because it can improve their quality of life.

5. Combination treatment strategies: Carfilzomib is often used as part of a combination treatment regimen with other drugs. For example, the combination treatment of carfilzomib with dexamethasone, raltolimus and other drugs has shown excellent results in the control of advanced myeloma and patient survival. The goal of these combined treatment strategies is to simultaneously attack cancer cells through different mechanisms of action and improve the therapeutic effect.

Carfilzomib, as a targeted therapy, has shown significant efficacy in the treatment of patients with advanced myeloma. It can control disease progression, prolong survival, improve quality of life, and provide new treatment options for patients with advanced myeloma. Although treatment may be associated with some side effects, the persistence of efficacy and survival advantage of carfilzomib have a positive impact on the lives and survival prospects of patients with advanced myeloma. Patients should receive treatment under the supervision of a medical professional and discuss with their doctor which treatment option is best for their individual situation. In addition, with continuous research and progress, the application prospects of carfilzomib are still expanding, and it is expected to play an increasing role in the treatment of advanced myeloma.

Carfilzomib has been launched in China and is included in medical insurance. Patients can purchase it domestically at a price of around 8,000 to 9,000 yuan. Please consult the local hospital pharmacy for specific prices. In foreign countries, the original drug of carfilzomib is mainly available, and the cheaper version is the European version of the original drug, which costs around 5,000. And the medicinal ingredients and efficacy are the same as those of domestic original medicines.